Notable Labs, Ltd. (NTBL) - Utang jangka dawa marang modal

This chart illustrating the price evolution of Notable Labs, Ltd. (NTBL) highlights business complexities stemming from stringent FDA and CLIA requirements, as well as high development costs for the PPMP AI system, with the metric standing at 0.00. The scaling model relies on cloud-based clinic access to analytics, eliminating the need for facilities to establish their own laboratories. Growth potential is based on the biotech sector's increasing interest in precision therapy forecasting tools.

Notable Labs Inc. - Utang jangka dawa marang modal NTBL (periode 21.02.2024 - 02.11.2024)

Notable Labs, Ltd. (NTBL) diversifies its revenue through AI software for pharma behemoths and its own therapeutic developments. By analyzing the long-term debt-to-equity profile on GURU.Markets, an investor can determine the business's degree of reliance on external borrowings. This metric compares liabilities with a maturity of over one year against the company's net assets. This allows for an assessment of financial stability and the risk of excessive leverage. A stable ratio confirms the safety of the expansion strategy.

Pesaing wigati

Rasio utang jangka dawa marang ekuitas BeiGene Ltd. (ONC)|Utang jangka dawa marang modal HALO|Utang jangka dawa marang modal Revolution Medicines Corp (RVMD)|Utang jangka dawa marang ekuitas Ascentage Pharma Group AAPG|CGON: Rasio utang jangka dawa marang modal|UroGen Pharma - Utang jangka dawa marang modal|Bicara Therapeutics Inc (BCAX) - Rasio utang jangka dawa marang ekuitas|PSNL: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Erasca Oncology (ERAS)|Utang jangka dawa marang ekuitas Delcath Systems, Inc.|YMAB: Koefisien utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas AURA (Aura Biosciences)|CADL (candeltx.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal ARAY (Accuray Inc.)|SLS - Rasio utang jangka dawa marang ekuitas|ACTU: Rasio utang jangka dawa marang ekuitas|CTOR - Utang jangka dawa marang modal|tuhurabio.com (HURA) - Utang jangka dawa marang ekuitas|Protara Therapeutics Inc - Koefisien utang jangka dawa marang modal|FATE (Fate Therapeutics Corp) - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Aadi Bio WHWK|Utang jangka dawa marang ekuitas TScan Therapeutics (TCRX)|championsoncology.com - Rasio utang jangka dawa marang modal|Utang jangka dawa marang ekuitas XBiotech XBIT|CEL-SCI Corp. (CVM) - Kewajiban jangka dawa marang modal|OSTX: Rasio utang jangka dawa marang ekuitas|Radiopharm Theranostics Ltd - Rasio silihan jangka dawa marang modal|ARTV: Utang jangka dawa marang modal|Adlai Nortye (ANL) - Utang jangka dawa marang modal|VERU (Veru) - Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas TPST|Utang jangka dawa marang ekuitas Xilio Therapeutics, Inc. (XLO)|Utang jangka dawa marang ekuitas RENB (renovarobio.com)|Utang jangka dawa marang modal MURA (Mural Oncology)|Kairos Pharma Limited (KAPA) - Kewajiban jangka dawa marang modal|OKUR: Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal GDTC (CytoMed Therapeutics)|curis.com (CRIS) - Utang jangka dawa marang ekuitas|APLM (Apollomics) - Utang jangka dawa marang ekuitas|THAR (Tharimmune, Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang modal Advanced Biomed Corp|Utang jangka dawa marang modal GNPX|Utang jangka dawa marang ekuitas CLDI (calidibio.com)|Utang jangka dawa marang ekuitas Sunshine Biopharma SBFM|Rasio tanggungan utang jangka dawa marang modal Xenetic Biosciences Inc. (XBIO)|SLRX: Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal PPBT (purple-biotech.com)|aoncology.com (AONC) - Utang jangka dawa marang ekuitas|BGNE (BeiGene Ltd.) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas CKPT|ELEV (Elevation Oncology Inc.) - Rasio silihan jangka dawa marang modal|Utang jangka dawa marang modal ICAD|ikenaoncology.com - Rasio utang jangka dawa marang modal|Viracta Therapeutics, Inc. - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal MorphoSys Inc (MOR)|NAYA - Utang jangka dawa marang ekuitas|AAPGV (Ascentage) - Rasio utang jangka dawa marang modal